Oaktree Capital Management’s Aspire Biopharma ASBP Stock Holding History

Oaktree Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-83	Closed	-$1.05M	–	257
2023 Q1	$1.05M	Hold	83	–	–	0.01%	271
2022 Q4	$1.03M	Hold	83	–	–	0.01%	308
2022 Q3	$1.01M	Hold	83	–	–	0.01%	329
2022 Q2	$998K	Buy	+83	New	+$994K	0.01%	321

Other funds holding ASBP

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

PSAMP

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Oaktree Capital Management's ASBP Position: Q2 2023 in Review

Oaktree Capital Management sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 83 shares — an estimated $1.05M sold.

Oaktree Capital Management first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $1.05M in Q1 2023. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

Oaktree Capital Management reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
Oaktree Capital Management sold 83 Aspire Biopharma shares in Q2 2023, an estimated $1.05M.
Oaktree Capital Management first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
Oaktree Capital Management's Aspire Biopharma position peaked at $1.05M in Q1 2023.
14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on Oaktree Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.